Potential of Control Conditions for Nonspecific Treatment-Effects in Noninferiority Trials-Reply

Affiliations

¹ Department of Psychiatry, Georgetown University Medical Center, Washington, DC.
² University of Caen Normandy and Caen University Hospital, Caen, France.
³ Department of Psychiatry, New York University Grossman School of Medicine, New York.

Comment

Elizabeth A Hoge et al. JAMA Psychiatry. 2023.

. 2023 May 1;80(5):523.

doi: 10.1001/jamapsychiatry.2023.0106.

¹ Department of Psychiatry, Georgetown University Medical Center, Washington, DC.
² University of Caen Normandy and Caen University Hospital, Caen, France.
³ Department of Psychiatry, New York University Grossman School of Medicine, New York.

No abstract available

Comment on

Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial.
Hoge EA, Bui E, Mete M, Dutton MA, Baker AW, Simon NM. Hoge EA, et al. JAMA Psychiatry. 2023 Jan 1;80(1):13-21. doi: 10.1001/jamapsychiatry.2022.3679. JAMA Psychiatry. 2023. PMID: 36350591 Free PMC article. Clinical Trial.
Potential of Control Conditions for Nonspecific Treatment Effects in Noninferiority Trials.
Budde H, Amatriain-Fernández S, Trautmann S. Budde H, et al. JAMA Psychiatry. 2023 May 1;80(5):522-523. doi: 10.1001/jamapsychiatry.2023.0102. JAMA Psychiatry. 2023. PMID: 36920358 No abstract available.